Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 10/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 2/20 | 0.30 |
| ▸ | LITAF | Q99732 | 2/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21099322 | 0.92 | KRAS (0.42) | KRASGPR119NTRK1PARP1SCN9A | |
| SCHEMBL21100015 | 0.91 | KRAS (0.43) | KRASGPR119NTRK1PARP1MAP4K4 | |
| SCHEMBL21050772 | 0.88 | KRAS (0.49) | KRAS | |
| SCHEMBL21100031 | 0.87 | KRAS (0.54) | KRASGPR119SCN9ATNFLITAF | |
| SCHEMBL21100011 | 0.85 | KRAS (0.64) | KRAS | |
| SCHEMBL21099288 | 0.84 | KRAS (0.51) | KRASGPR119NTRK1PARP1MAP4K4 | |
| SCHEMBL21099403 | 0.84 | KRAS (0.53) | KRASNTRK1TNFLITAF | |
| SCHEMBL21099226 | 0.81 | KRAS (0.66) | KRAS | |
| SCHEMBL21050982 | 0.79 | KRAS (0.45) | KRAS | |
| SCHEMBL30231218 | 0.79 | KRAS (0.46) | KRASGPR119NTRK1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | KRAS 272/4885GPR119 945/4885NTRK1 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.